Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2019-12-12 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-12-12 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-12-05 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 19, 2019, by Vir Biotechnology, Inc. It announces the issuance of a press release with financial results for the quarter ended September 30, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a notification of the earnings release. According to the 'Menu vs Meal' rule, such a short document that announces and attaches a press release of financial results should be classified as an Earnings Release (ER) because the press release is included and the document is focused on announcing quarterly financial results. The document is not a full quarterly report (IR) but an initial announcement of quarterly financial results, fitting the Earnings Release category.
2019-11-19 English
ARCH VENTURE FUND IX, L.P. - SCHEDULE 13D - VIR BIOTECHNOLOGY, INC.
Major Shareholding Notification
2019-11-08 English
SC 13G
Major Shareholding Notification
2019-10-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.